血蛋白水平和肝细胞癌:一个门德尔的随机化研究,药物查含义
Longhui Xie1,2, Dekun Song1,3, Jianwei Lan1
1Department of Hepatobiliary Surgery, Tianjin Medical University General Hospital, Tianjin, China.
贝利诺斯塔特通过增强免疫细胞活性和减少瘤生长来治疗肝细胞癌 (HCC) 是有前途的. 需要进一步的临床研究来证实它在HCC患者中的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 是癌症死亡的主要原因.
- 对于HCC治疗,迫切需要新的治疗策略.
- 识别关键蛋白质和治疗剂对于改善结果至关重要.
研究的目的:
- 使用孟德尔随机化识别与HCC风险相关的蛋白质.
- 通过药物丰富和分子对接来发现HCC的潜在治疗剂.
- 在临床前模型中评估已识别的药物的疗效.
主要方法:
- 门德尔的随机化用于蛋白质关联分析.
- 潜在药物的体外和体内疗效研究.
- 单细胞表达造型和临床样本分析.
主要成果:
- 已经确定了16种与HCC病变发生相关的蛋白质.
- 贝利诺斯塔特显著增强了T细胞介导的对HCC细胞的细胞毒性.
- 贝利诺斯塔特在体内有效降低瘤生长,并在瘤微环境中调节免疫细胞.
结论:
- 贝利诺斯塔特是肝细胞癌的潜在治疗剂.
- 贝利诺斯塔特调节免疫反应并抑制瘤生长.
- 需要进一步对贝利诺斯塔特进行HCC的临床研究.
更多相关视频
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
相关概念视频
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Drug Distribution: Plasma Protein Binding
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
Physiological Pharmacokinetic Models: Assumption with Protein Binding
